BioCentury | Feb 6, 2021
Deals

Feb. 5 Quick Takes: Veracyte taking out Decipher in cancer dx merger; plus V-Bio, Branson-and-Me, Elucidata, Osel

...is acquiring. By Jeff Cranmer, Executive Editor Veracyte Inc. (NASDAQ:VCYT) is acquiring fellow cancer diagnostics company Decipher Biosciences...
BioCentury | Jan 20, 2021
Finance

IPO queue upswelling: Data Byte

...has raised. Friday’s crop of filings also included a pair of diagnostics companies; genomic testing play Decipher Biosciences...
...companies are seeking a listing on NASDAQ. " title="Interactive or visual content" frameborder="0" scrolling="no" style="width:100%;height:480px;"> Winnie Pong Decipher Biosciences Lucira...
BioCentury | Feb 10, 2017
Company News

GenomeDx, Astellas deal

...GenomeDx Biosciences Inc. , Vancouver, B.C. Astellas Pharma Inc. (Tokyo:4503), Tokyo, Japan Business: Pharmacogenetics Nora Weintraub Xtandi Astellas Pharma Inc. GenomeDx Biosciences...
BioCentury | Feb 9, 2015
Company News

GenomeDx Biosciences sales and marketing update

...prostate cancer. It was developed under a 2009 deal with the Mayo Clinic (Rochester, Minn.). GenomeDx Biosciences...
BioCentury | Oct 20, 2014
Clinical News

Decipher Prostate Cancer Classifier regulatory update

...under a 2009 deal with the Mayo Clinic (Rochester, Minn.) (see BioCentury, May 6, 2013). GenomeDx Biosciences...
BioCentury | Jun 23, 2014
Company News

GenomeDx Biosciences Inc sales and marketing update

...covered lives, which brings the total covered lives to “nearly” 120 million for the test. GenomeDx Biosciences...
BioCentury | Oct 31, 2013
Distillery Therapeutics

Indication: Cancer

...a nonexclusive license to create commercial research assays for the detection of lncRNAs, including SChLAP1; GenomeDx Biosciences...
BioCentury | Oct 7, 2013
Finance

Deciphering GenomeDx

...Deciphering GenomeDx While some investors are fleeing the diagnostic space, a series B round for GenomeDx Biosciences...
BioCentury | Oct 7, 2013
Financial News

GenomeDx Biosciences completes venture financing

GenomeDx Biosciences Inc. , Vancouver, B.C. Business: Diagnostic Date completed: 9/30/13 Type: Venture financing Raised: Not disclosed Investors: Merck Global Health Innovation Fund; Baird Venture Partners; Aeris Capital AG; CD Ventures WIR Staff Diagnostic...
BioCentury | Oct 1, 2013
Financial News

GenomeDx closes series B round

...Molecular diagnostic company GenomeDx Biosciences Inc. (Vancouver, B.C.) raised an undisclosed amount in a series B round...
Items per page:
1 - 10 of 15
BioCentury | Feb 6, 2021
Deals

Feb. 5 Quick Takes: Veracyte taking out Decipher in cancer dx merger; plus V-Bio, Branson-and-Me, Elucidata, Osel

...is acquiring. By Jeff Cranmer, Executive Editor Veracyte Inc. (NASDAQ:VCYT) is acquiring fellow cancer diagnostics company Decipher Biosciences...
BioCentury | Jan 20, 2021
Finance

IPO queue upswelling: Data Byte

...has raised. Friday’s crop of filings also included a pair of diagnostics companies; genomic testing play Decipher Biosciences...
...companies are seeking a listing on NASDAQ. " title="Interactive or visual content" frameborder="0" scrolling="no" style="width:100%;height:480px;"> Winnie Pong Decipher Biosciences Lucira...
BioCentury | Feb 10, 2017
Company News

GenomeDx, Astellas deal

...GenomeDx Biosciences Inc. , Vancouver, B.C. Astellas Pharma Inc. (Tokyo:4503), Tokyo, Japan Business: Pharmacogenetics Nora Weintraub Xtandi Astellas Pharma Inc. GenomeDx Biosciences...
BioCentury | Feb 9, 2015
Company News

GenomeDx Biosciences sales and marketing update

...prostate cancer. It was developed under a 2009 deal with the Mayo Clinic (Rochester, Minn.). GenomeDx Biosciences...
BioCentury | Oct 20, 2014
Clinical News

Decipher Prostate Cancer Classifier regulatory update

...under a 2009 deal with the Mayo Clinic (Rochester, Minn.) (see BioCentury, May 6, 2013). GenomeDx Biosciences...
BioCentury | Jun 23, 2014
Company News

GenomeDx Biosciences Inc sales and marketing update

...covered lives, which brings the total covered lives to “nearly” 120 million for the test. GenomeDx Biosciences...
BioCentury | Oct 31, 2013
Distillery Therapeutics

Indication: Cancer

...a nonexclusive license to create commercial research assays for the detection of lncRNAs, including SChLAP1; GenomeDx Biosciences...
BioCentury | Oct 7, 2013
Finance

Deciphering GenomeDx

...Deciphering GenomeDx While some investors are fleeing the diagnostic space, a series B round for GenomeDx Biosciences...
BioCentury | Oct 7, 2013
Financial News

GenomeDx Biosciences completes venture financing

GenomeDx Biosciences Inc. , Vancouver, B.C. Business: Diagnostic Date completed: 9/30/13 Type: Venture financing Raised: Not disclosed Investors: Merck Global Health Innovation Fund; Baird Venture Partners; Aeris Capital AG; CD Ventures WIR Staff Diagnostic...
BioCentury | Oct 1, 2013
Financial News

GenomeDx closes series B round

...Molecular diagnostic company GenomeDx Biosciences Inc. (Vancouver, B.C.) raised an undisclosed amount in a series B round...
Items per page:
1 - 10 of 15